

1 **Dietary Epicatechin Is Available to Breastfed Infants through Human Breast**
2 **Milk in the Form of Host and Microbial Metabolites**

3 Olha Khymenets, †, ‡ Montserrat Rabassa, †, ‡ María Rodríguez-Palmero,§ Montserrat Rivero-
4 Urgell,§ Mireia Urpi-Sarda, ‡ Sara Tulipani, ‡,|| Pilar Brandi,⊥ Cristina Campoy,⊥,# Celestino
5 Santos-Buelga,∇ and Cristina Andres-Lacueva*, ‡

6 ‡ *Biomarkers and Nutrimetabolomics Laboratory, Nutrition and Food Science Department, Food*
7 *Technology Reference Net (XaRTA), Nutrition and Food Safety Research Institute (INSA), Faculty of*
8 *Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain*

9 § *Laboratorios Ordesa S.L., Barcelona Science Park, 08028 Barcelona, Spain*

10 // *Biomedical Research Institute (IBIMA), Service of Endocrinology and Nutrition, Hospital Complex*
11 *Virgen de la Victoria, 29071 Malaga, Spain*

12 ⊥ *Excellence Centre for Paediatric Research, Biomedical Research Centre, Health Sciences*
13 *Technological Park, Hospital Universitario San Cecilio, 18012 Granada, Spain*

14 # *Department of Paediatrics, School of Medicine, University of Granada, 18012 Granada, Spain*

15 ∇ *GIP-USAL, Faculty of Pharmacy, University of Salamanca, 37007 Salamanca, Spain*

16

17 **ABSTRACT**

18 Polyphenols play an important role in human health. To address their accessibility to a breastfed
19 infant, we planned to evaluate whether breast milk (BM) (colostrum, transitional, and mature)
20 epicatechin metabolites could be related to the dietary habits of mothers. The polyphenol
21 consumption of breastfeeding mothers was estimated using a food frequency questionnaire and 24 h
22 recalls. Solid-phase extraction–ultra performance liquid chromatography–tandem mass spectrometry
23 (SPE–UPLC–MS/MS) was applied for direct epicatechin metabolite analysis. Their bioavailability
24 in BM as a result of dietary ingestion was confirmed in a preliminary experiment with a single dose
25 of dark chocolate. Several host and microbial phase II metabolites of epicatechin were detected in
26 BM among free-living lactating mothers. Interestingly, a modest correlation between
27 dihydroxyvalerolactone sulfate and the intake of cocoa products was observed. Although a very low
28 percentage of dietary polyphenols is excreted in BM, they are definitely in the diet of breastfed
29 infants. Therefore, evaluation of their role in infant health could be further promoted.

30 **KEYWORDS:**

31 human breast milk, dietary polyphenols, cocoa, epicatechin host and microbiota metabolites,
32 breastfeeding

33 **INTRODUCTION**

34 Human breast milk (BM) is the optimal food for newborns and infants because it supplies nutrients
35 and biologically active elements that are essential for their development and health.¹ Along with its
36 main nutrients, it also supplies minor compounds, such as vitamins and micronutrients, which play
37 important roles in the development and health of infants.² Despite the accumulated knowledge in the
38 field of dietary polyphenols,^{3,4} currently, little is known about their bioavailability in human BM of
39 lactating mothers and their accessibility to breastfed infants. Accordingly, the effect of the
40 consumption of dietary polyphenols through BM on the health of infants has not yet been widely
41 studied. Thus far, only a few studies have addressed the question of the excretion of dietary
42 polyphenols in human BM under controlled dietary ingestion,^{5–7} and even fewer studies have

43 addressed their presence in the BM of lactating mothers under free-living conditions.^{8,9} However,
44 all of them measured the enzymatically hydrolyzed fraction of corresponding polyphenols, without
45 taking into account the nature of the metabolites available in BM. Recently, the importance of
46 investigating the metabolites of dietary polyphenols was highlighted.³ To establish the health effects
47 of polyphenol intake by infants, it is essential to have information on their disposition in BM, which
48 is related to the previous dietary intake of a lactating woman. With the intention of assessing the
49 delivery of polyphenols of a dietary origin to infants through breastfeeding, we planned to estimate
50 whether the presence of epicatechin metabolites in BM could be related to the dietary habits of
51 lactating mothers. Cocoa products are among the richest sources of polyphenols in our diets.¹⁰ One
52 of the most well-accepted and widely consumed cocoa products in the world is chocolate. In relation
53 to the objectives of the present study, we consider dark chocolate (DCh) to be an appropriate food
54 element to provide close to real-life ingestion of one of the most representative dietary polyphenols:
55 flavan-3-ols. In addition, the bioavailability of flavanols, especially epicatechin, is one of the most
56 well-understood among dietary polyphenols¹¹ and has also been extensively studied by our
57 group.^{12,13} Therefore, flavanol-rich DCh could be a good dietary choice to approximate the
58 bioavailability and excretion of epicatechin in BM. In addition, a cocoa component in foods is easy
59 to track in the dietary records of free-living subjects as a result of its relatively integral consumption
60 and because its presence in food can be easily recognized and recalled by subjects. Therefore, we
61 anticipate that the presence in BM of epicatechin metabolites might reflect dietary epicatechin
62 consumption of either a total or specifically epicatechin-rich food (e.g., cocoa) origin by lactating
63 women.

64 **MATERIALS AND METHODS**

65 **Study Design, Subjects, and Sampling. Preliminary Experiment on Epicatechin BM**
66 **Bioavailability.** Two healthy lactating mothers (aged 32 and 37 and weighing 68 and 63 kg,
67 respectively) in the 6th month of the postpartum period kindly provided their BM (mature milk) at
68 several time points over a 12 h period on a voluntary basis. Neither woman smoked or took
69 medication. The acute ingestion of DCh was carried out in the morning, prior to any other food intake.

70 The DCh consumed was from a domestic supply, and both volunteers reported on the amount (g)
71 consumed and percentage of cocoa in the chocolate (according to the manufacturer) (Table S1 of the
72 Supporting Information). During the intervention day, no other cocoa-containing products were
73 consumed by either volunteer. The women reported their 24 h dietary habits on the day prior to the
74 collection of BM samples. While total milk was collected from one breast using an electric pump
75 over defined time periods after acute DCh ingestion, babies were nourished from the other breast on
76 demand. The volume of collected BM was recorded. Free-Living Population Study. A total of 11
77 breastfeeding women (mean age of 33.2 years) under free-living conditions participated in the
78 population study. They were recruited in their 30th week of pregnancy from the Barcelona Science
79 Park and the San Cecilio University Hospital in Granada (Figure 1). Detailed information on the
80 eligibility criteria is disclosed in the Supporting Information. All participants had read the study
81 protocol, approved by the Ethics Committee of San Cecilio University Hospital in Granada and the
82 Bioethics Committee of the University of Barcelona (IRB00003099), and had signed an informed
83 consent form. The samples, metrics, and dietary data collection were performed in both recruiting
84 centers. Manipulation of the samples, evaluation of dietary records, and analyses were performed by
85 the Barcelona University group. A food frequency questionnaire (FFQ) was provided on the day of
86 inclusion in the study (Figure 1). After a baby was born, three types of BM samples, colostrum (1–4
87 days postpartum), transitional (5–15 days postpartum), and mature (>30 days postpartum), and 24 h
88 dietary recalls (24 h DR) completed on the previous day were collected from each volunteer. Up to
89 30–50 mL of BM was collected per sample in the morning or through the day using a manual or
90 electric pump. However, in the course of the study, several dietary records and some BM samples
91 were not available (Figure 1). All of the collected BM samples (from the preliminary experiment and
92 population study) were labeled, immediately stored at $-20\text{ }^{\circ}\text{C}$ (in home freezers), and shortly
93 afterward transferred in dry ice to the laboratory freezers, where they were stored at $-80\text{ }^{\circ}\text{C}$ until
94 analysis.

95 **Dietary Assessment of Polyphenol Intake.** Food intake (g/ day) was evaluated using three 24 h DR.
96 Dietary total and individual flavan-3-ol monomer (from here on flavan-3-ols will refer to monomers

97 only) intake was estimated using our food composition database on polyphenols.¹⁴ This was based
98 on three United States Department of Agriculture (USDA) databases^{15–17} and the Phenol- Explorer
99 database.¹⁸ The FFQ, developed and validated in the Spanish population,¹⁹ was applied on the day
100 of enrolment to evaluate food intake (g/day) over the previous 3 months by pregnant women in a free-
101 living population study.

102 **Determination of Epicatechins and Their Metabolites in BM Samples.** On the day of analysis, a
103 1 mL aliquot of the BM sample was thawed in an ice bath, acidified with 25 μ L of phosphoric acid
104 (35%), sonicated for 15 min at room temperature, and afterward centrifuged at 15900g for 10 min at
105 4 °C. Through gentle aspiration, 0.8 mL of acidified aqueous phase of BM was collected and used
106 for solid-phase extraction (SPE). The concentrations of (–)-epicatechin (EpiCat), O-methyl-
107 epicatechin (MetEpiCat), and colon microbiotagenerated metabolites, such as 5-(3',4' -
108 dihydroxyphenyl)- γ -valerolactone (DHPV) and 5-(3' -methoxy-4' -hydroxyphenyl)- γ -
109 valerolactone (MHPV), along with their corresponding phase II conjugate sulfates (Sulf) and
110 glucuronides (Gluc) in BM, were analyzed according to the earlier published methodology,²⁰ with a
111 slightly modified elution step. Then, the retained epicatechin metabolites were eluted by applying 0.5
112 mL of basic methanol (0.1% ammonia) after 1 mL of acidified methanol (0.1% formic acid) to
113 optimize both glucuronide and sulfate extraction (>75% recovery; data not shown).²¹ The
114 reconstituted-immobile- phase samples were used for ultra performance liquid chromatography–
115 tandem mass spectrometry (UPLC–MS/MS) analysis. Ethyl gallate served as the internal standard
116 (IS). The previously established methodology was used for UPLC–MS/MS analysis of epicatechin
117 metabolites.^{12,20} The epicatechin metabolites were identified according to the available standards
118 (EpiCat, Cat, MetEpiCat, EpiCat-Gluc-2, and EpiCat-Sulf-1) and as a result of the previously
119 described mass chromatographic behavior of compounds^{12,20} (Table S2 of the Supporting
120 Information). Calibration curves were constructed in the range of 5–2000 μ g/L with available
121 standards in aqueous extracts of BM and subjected to the same procedure as the samples. As a result
122 of the fact that standards for phase II metabolites were not available, the concentrations of all sulfated,
123 glucuronidated, and methylated metabolites were approximated using curves of in-house synthesized

124 EpiCat-Sulf-1, EpiCat-Gluc-2, and MetEpiCat, respectively, and the results were expressed as their
125 equivalents.²⁰ These compounds were synthesized and characterized as previously published.²² The
126 purity of purchased standards [(-)-epicatechin, (+)-catechin, and ethyl gallate from Sigma-Aldrich
127 (St. Louis, MO)] was of analytical grade, and the purity of synthesized standards was ≥ 98 , ≥ 98 , and
128 $\geq 96\%$, respectively, as reported in our previous studies applying this methodology.^{12,20}

129 **Statistical Analysis.** Dietary intake of polyphenols is shown as the mean and standard deviation
130 (SD). The contribution of each food to total dietary polyphenols and flavan-3-ol intake, in total and
131 specifically that of cocoa origin, and the contribution of flavan-3-ol to the polyphenol intake were
132 calculated as a percentage. The Friedman test was used to compare the consumption of polyphenols
133 among the three phases of lactation. We used Spearman correlations to assess whether flavan-3-ol
134 and epicatechin intakes were correlated to DHPVSulf- 2. SPSS statistical analysis system, version
135 18.0 (SPSS), was used, and the significance level for the performed statistical analyses was <0.05 .

136 **RESULTS AND DISCUSSION**

137 **Epicatechin Metabolites in BM after Acute DCh Ingestion.** In accordance with the habitual dietary
138 consumption evaluated by 24 h DR collected on pre-intervention day, DCh was the principal dietary
139 source of flavan-3-ols (78– 92%) and epicatechin (92–96%) consumed during the intervention day
140 by both volunteers (Table S1 of the Supporting Information). In both lactating women, the acute DCh
141 intervention was estimated to provide an intake of around 80 mg of DCh-derived flavan-3-ol
142 monomers, of which about 48% corresponded to epicatechin (Table S1 of the Supporting
143 Information). Therefore, the DCh epicatechin content was estimated to be within the ranges reported
144 for other commercially available DChs.²³

145 The DCh intake challenge led to the direct identification of two groups of epicatechin metabolites in
146 the BM samples of both volunteers collected over 12 h after ingestion: (i) host metabolites of
147 epicatechin, EpiCat-Sulf-1 and EpiCat-Sulf-2, EpiCat-Gluc-4, and Met-EpiCat-Sulf-3, and (ii)
148 microbial metabolites, DHPV-Sulf-2, DHPV-Gluc-1 and DHPV-Gluc-2, MHPV-Sulf-1 and MHPV-

149 Sulf-2, and MHPV-Gluc-1.12,20 The selected chromatograms of the detected epicatechin
150 metabolites in the BM samples are represented in Figure S1 of the Supporting Information.

151 BM is a special biological compartment linked closely to plasma, but on the other hand, similar to
152 urine, it can accumulate excreted compounds.²⁴ Although we did not have corresponding standards,
153 it is very likely that the main detected host metabolites correspond to the major metabolites of
154 cocoaderived epicatechin recently described in postprandial plasma and urine:^{25,26} EpiCat-3'-O-
155 Gluc (as EpiCat-Gluc-4), EpiCat-3'-O-Sulf (as EpiCat-Sulf-2), and 3'-Methyl-EpiCat-5-O-Sulf
156 (as Met-EpiCat-Sulf-3). In general, their levels in the BM samples were quite low, even at maximum
157 concentration rates (nmol/L) (Figure S1 of the Supporting Information and panels A and B of Figure
158 2), being close to the plasmatic postprandial levels detected after intake of 2 times higher dose of
159 DCh.²⁶ This was also in agreement with the BM ranges of other polyphenols previously reported in
160 dietary intervention volunteers^{6–8} and in some populations of free-living lactating mothers.^{5,9} Other,
161 less abundant metabolites could not be detected as a result of their very low, several times lower than
162 detected, metabolite²⁶ concentrations. The changes in the BM concentrations of the detected host
163 metabolites were very similar in both volunteers (Figure 2B).

164 Continuously collected samples from volunteer 2 were used to evaluate the BM excretion kinetics
165 of detected host epicatechin metabolites over 12 post-intervention hours (Figure 2A). The peaks of
166 maximum concentration for each metabolite were defined by visual inspection of excretion graphs.
167 Thus, the highest levels of EpiCat-Sulfs and EpiCat- Gluc metabolites were reached in BM 4 h after
168 DCh intake and after 6 h for Met-EpiCat-Sulf in both sample sets (Figure 2B). Dietary epicatechin
169 was rapidly absorbed in the small intestine, and its metabolites were quickly eliminated from plasma
170 within 6–8 h and excreted in urine.²⁶ Our data showed that the main epicatechin host metabolites
171 were still present in the BM at detectable levels 12 h after DCh ingestion (panels A and B of Figure
172 2). According to the dietary recalls, no other potent source of flavanols other than DCh was consumed
173 on the intervention day by either volunteer (Table S1 of the Supporting Information). Therefore, this
174 accumulation of DChderived host epicatechin metabolites in the BM resembled that previously
175 reported for urine, where they were mostly excreted between the 5th and 10th postprandial hour and

176 were still present at lower concentrations after 10 h.²⁶ Unfortunately, we did not collect either blood
177 or urine samples from the two volunteers within the present study. However, the relation between the
178 plasmatic, urinary, and BM kinetics of epicatechin metabolites should be further studied, because it
179 will indicate in detail the bioavailability, excretion, and accumulation of dietary polyphenols in BM.
180 In addition to host metabolites, the only microbial-derived metabolite of epicatechin, DHPV-Sulf-2,
181 was detected in the set of BM samples of volunteer 2 (Table S3 of the Supporting Information). In
182 contrast, other microbial metabolites were also detected in all of the BM samples of volunteer 1:
183 DHPV-Sulf-1, DHPV-Gluc-2, MHPV-Sulf-1, MHPV-Sulf-2, and MHPV-Gluc- 1, along with the
184 most pronounced DHPH-Sulf-2 metabolite (Figure S1 and Table S3 of the Supporting Information).
185 All of them, except DHPV-Sulf-1, were increasing in concentration toward the end of the BM sample
186 collection period (12 h). Unfortunately, there are no reported data on the urine or plasmatic kinetics
187 of microbial ring-fusion metabolites of cocoaderived epicatechin to be compared to our BM results.
188 According to recently reported data on tea epicatechins,²⁷ first-stage microbial metabolites
189 (valerolactones) appeared in plasmatic circulation with a 2–4 h lag time and at a maximum
190 concentration in 4–8 h, exceeding those of host epicatechin metabolites by 1 order of magnitude.
191 They remained in circulation for about 20 h after single-dose consumption of black tea. On the basis
192 of these pharmacokinetic data, we assume that the BM kinetics of the microbial metabolites could
193 not be evaluated within the present study as a result of the relatively short time for postprandial
194 sample collection. The late appearance of the ring-fusion metabolites in BM is due to the fact that
195 they are generated through microbiota catabolic activities and, as result, are absorbed in the large
196 intestine.²⁸ We assume that, in contrast to volunteer 2, who did not consume any cocoa products
197 prior to the intervention, epicatechin microbial metabolites were detected in the preintervention (0 h)
198 and early (2–8 h) postprandial samples of volunteer 1 most likely as a result of the consumption of
199 DCh from the previous day within her habitual diet (data not shown). In general, our data on microbial
200 epicatechin metabolites are also in line with those previously reported, where the main microbial
201 metabolite in 24 h urine after longterm cocoa powder consumption was DHPV-Sulf-2, along with the
202 main host metabolites EpiCat-Gluc-4, EpiCat-Sulf-2, and Met-EpiCat-Sulf-2.¹² In support of our
203 findings, in the study with tea polyphenols, it was observed that sulfated conjugates of valerolactones

204 were almost twice more represented in plasma than glucuronidated forms.²⁷ Thus, the authors
205 suggested that sulfation was preferred over glucuronidation at the site of valerolactone metabolism.²⁷
206 The 2 h fractionated samples from volunteer 2 showed approximated 12 h cumulative excretion of
207 the detected host metabolites in BM. It was not possible to conduct analysis for volunteer 1, because
208 the collection of samples was interrupted as a result of lactating circumstances. Thus, the combined
209 12 h excretion of the host metabolites in BM, expressed in catechin equivalents, was estimated to
210 account for about 0.01% (assuming equal excretion in both breasts) of the chocolateingested
211 epicatechin (Table S3 of the Supporting Information). Considering just non-colonic metabolites, the
212 bioavailability value during the first 12 postprandial hours observed in this study would provide a
213 breastfed child with about 3.8 μg of catechin equivalent. This approximately corresponds to a
214 cumulative dose of 0.772 $\mu\text{g}/\text{kg}$ (for a baby weighing 5 kg) spread over 12 h,²⁹ when the single dose
215 of the lactating mother was estimated to be about 0.61 mg/kg (for a woman weighing 63 kg) as DCh-
216 derived epicatechin. Thus, the dose for the child appears to be 3 orders of magnitude lower than that
217 of the mother. Unfortunately, we cannot take into account the metabolites generated by colonic
218 microbiota for mother and infant dose approximation, although their weight in relation to epicatechin
219 metabolism and disposition is expected to be essential.^{27,28} On the other hand, other potential
220 sources of epicatechin and valerolactone phase II metabolites, such as procyanidins,¹² were not
221 considered in our preliminary experiment. Estimation of the accessibility of dietary polyphenols to
222 breastfed infants could be especially relevant in the light of recent reports accentuating their potential
223 to modulate gut microbiota activities.^{30,31}

224 **Epicatechin in BM of Free-Living Lactating Women.**

225 Among the 11 women participating in our population study, FFQs were collected from 9 volunteers.
226 All three 24 h DRs were available only for 8 volunteers, whereas the second and third 24 h DRs
227 (corresponding to transition and mature milk collections) were available for 10 volunteers; for one of
228 them, it was repeated twice for transition, and for another, it was repeated twice for mature milk
229 collection (Figure 1 and Table S4 of the Supporting Information). From the 33 samples planned to be
230 collected for epicatechin metabolite analysis, 4 colostrum samples and 1 mature milk sample from

231 different volunteers and all three BM samples from one volunteer were not available as a result of
232 lactating circumstances. In total, 10 volunteers participated in the study, providing 24 BM samples
233 matched to corresponding dietary records (Figure 1 and Table S4 of the Supporting Information). The
234 total polyphenol consumption in our population was 1104.97 ± 465.97 mg/day according to the FFQs,
235 which was higher than that assessed by the 24 h DRs, where the average consumption corresponded
236 to about 751.58 mg/day (Table S5 of the Supporting Information). According to the FFQs and average
237 24 h DRs, cocoa polyphenols made a moderate contribution to the total dietary polyphenol
238 consumption in our free-living population, 8 and 9%, respectively (Table S5 of the Supporting
239 Information), which was in line with recent data (6.7%) on the south European region.³² In general,
240 daily flavan-3-ol consumption by free-living breastfeeding mothers was in the range of 1.8–47.5
241 mg/day (Table S4 of the Supporting Information), on average 18.29 ± 11.83 mg/day, which was
242 relatively lower than that recently reported for habitual consumption among Spanish adult males (~24
243 mg/day)³² and females (~26 mg/day).³³ However, the impact of cocoa products on the provision of
244 a relatively small percentage of dietary flavan-3-ols (~4% of total polyphenols according to the FFQ
245 and average 24 h DRs) was noticeable: 44% (according to the FFQs) and in the range of 13–54%
246 during the three stages of lactation (according to the 24 h DRs) (Table S5 of the Supporting
247 Information). According to the FFQs, DCh was the principal source of flavan-3-ols, providing 23%
248 of the total flavan-3-ol monomer consumption, followed by cocoa (14%), green tea (9%), apples
249 (8%), cocoa products (7%), black tea (5%), red grapes (4%), and white grapes (2%) (data not shown).
250 Thus, cocoa provided on average more than 30% of the flavan-3-ols and about 40% of the epicatechin
251 consumed within their habitual diet by breastfeeding mothers (Table S5 of the Supporting
252 Information), which was much higher than the 6.7% reported recently for the southern region of
253 Europe.³² Among the dietary records matched to BM samples, there were 6 participants who
254 declared no consumption of cocoa products over the 24 h prior to sample collection (Table S4 of the
255 Supporting Information). Overall, the consumption of both total polyphenols and flavan-3-ols,
256 assessed by 24 h DR, did not differ significantly ($p = 0.88$) among the three lactating periods. Both
257 global dietary and specifically cocoa origin daily intakes of flavan-3-ols and epicatechin correlated
258 highly (minimum $r > 0.75$ at $p < 0.025$) between the FFQs and the average data from the parallel 24

259 h DRs (data not shown), thereby ensuring the consistency of our dietary evaluations over time. Using
260 the previously tested DCh intervention experiment methodology, we were able to detect various
261 epicatechin metabolites in BM samples collected from free-living lactating mothers (Table S4 of the
262 Supporting Information). The main phase II host metabolites reported in the preliminary study
263 (EpiCat-Gluc-4, EpiCat-Sulf-2, and Met-EpiCat-Sulf-3) were sporadically identified in some of the
264 samples of the population study. On the other hand, the most pronounced metabolite, DHPV-Sulf-2,
265 which belongs to the colonic microbial epicatechin metabolites, was detected in practically all of the
266 samples (Table S4 of the Supporting Information), whereas other microbial metabolites were only
267 detected in some of them. On the whole, the levels of detected host metabolites were low, only up to
268 several tens of nanomoles per liter (Table S4 of the Supporting Information). A recent study with
269 free-living lactating mothers reported a higher concentration of epicatechin in BM (63.7–828.5
270 nmol/L).⁹ On the one hand, our methodology differs from that applied in the American study, in
271 which total enzymatically hydrolyzed epicatechin was analyzed. In addition, the collection of BM
272 samples differs in the methodology. On the other hand, the dietary habits during lactation might be
273 different among countries, providing distinct dietary uptake of flavan-3-ols. Unfortunately, no data
274 on the dietary habits of American breastfeeding mothers were collected within the study⁹ to compare
275 to our population. Samples collected during the population study corresponded to three different
276 stages of lactation: colostrum, transition, and mature milk (Figure 1). Changes in the concentration
277 of the detected metabolites over these periods could not be examined because of their sporadic
278 detection in a limited number of samples. For the same reason, no correlation studies could be
279 performed between the epicatechin metabolites detected in BM and the dietary data of volunteers,
280 with the exception of DHPV-Sulf-2. The levels of DHPV-Sulf-2 detected in practically all of the BM
281 samples were correlated with the dietary epicatechin and flavan-3-ol consumption reported by both
282 the FFQ (data not shown) and 24 h DR (Table 1), but no relation was observed. After consideration
283 of the heterogeneity in the types of cocoa product and in the percentage of cocoa flavan-3-ol
284 consumption (Table S4 of the Supporting Information) for the three periods of lactation and the
285 physiological specificity of the colostrum secretion,^{1,34} the colostrum samples
286 (n = 3) were withdrawn from the analysis. As a result, the analysis performed on the transition and

287 mature sample sets, as independent ones, showed a moderate positive correlation ($r = 0.434$; $p =$
288 0.049) between 24 h consumption of cocoa epicatechin and levels of detected DHPV-Sulf-2 in these
289 BM samples (Table 1). The fact that the epicatechin host metabolites were detected in BM only
290 sporadically but colonic metabolites were detected more often was supported by the data on the BM
291 kinetics of these metabolites observed in our preliminary bioavailability experiment. In our free-
292 living population, dietary data were recorded 24 h prior to BM sampling, and therefore, the chance
293 of detecting low-abundant host metabolites would be limited to the late, close-to-sampling
294 epicatechin consumption as a result of their short circulation time. However, as a result of the
295 specificity of the colonic metabolism, the appearance of microbial metabolites of epicatechin could
296 be extended to a much longer period at more elevated levels than host metabolites,^{12,27} thereby
297 increasing the possibility of being monitored during an uncontrolled study. Therefore, valerolactones
298 could be more readily detected in BM and, thus, used in relation to 24 h previous epicatechin
299 consumption. Although our data showed that the concentration of the main microbial epicatechin
300 metabolite DHPV-Sulf-2 in BM could be correlated with cocoa epicatechin intake within an
301 uncontrolled habitual diet, we are aware of the small size of our population. Therefore, a larger study
302 should be carried out to confirm this association. Our study demonstrates that dietary polyphenols,
303 such as cocoa-derived epicatechin, are bioavailable to breastfed infants through maternal milk as a
304 phase II host and colonic microbial-derived metabolites. According to the approximated cumulative
305 excretion data, only a very small amount of dietary-ingested epicatechin could be provided with BM
306 within the first 12 postprandial hours as host epicatechin metabolites. However, it seems that
307 microbial metabolites represent another important part of the BM-excreted epicatechin metabolites.
308 Both host and first-stage microbial metabolites (valerolactones) could even be detected in BM
309 samples collected from lactating mothers under non-controlled free-living conditions. However, as a
310 result of its relatively elevated concentration and timely prolonged excretion rates compared to other
311 epicatechin metabolites, only the principal first-stage microbial metabolite DHPV-Sulf-2 could be
312 used in correlation analysis. Thus, its presence in BM was modestly correlated with dietary intake of
313 cocoa epicatechin by breastfeeding mothers during transition and mature periods of lactation. Our

314 findings provide support for further potential research evaluating the impact of dietary polyphenols
315 on the health of infants.

316 **ASSOCIATED CONTENT**

317 **The Supporting Information** is available free of charge on the ACS Publications website at DOI:
318 10.1021/acs.jafc.6b01947. Eligibility criteria for the study population, DCh flavan-3-ol and
319 epicatechin ingestion by volunteers in the bioavailability experiment (Table S1), mass spectrometric
320 and chromatographic characteristics of the compounds used for the present UPLC–MS/MS analysis
321 (Table S2), extracted chromatograms of identified epicatechin metabolites in BM samples (Figure
322 S1), brief summary of the excretion kinetics for the epicatechin metabolites detected in BM after
323 acute DCh intake by lactating mothers (Table S3), cocoaderived and total flavan-3-ol consumption
324 by free-living lactating mothers and epicatechin metabolites detected in BM samples (Table S4), and
325 dietary intake of flavan-3-ols (monomers) and epicatechin in total and specifically of cocoa origin
326 by breastfeeding mothers in the population study (Table S5) (PDF)

327 **AUTHOR INFORMATION**

328 **Corresponding Author**

329 *Telephone: +34-934034840. Fax: +34-934035931. E-mail: candres@ub.edu.

330 **Author Contributions**

331 † Olha Khymenets and Montserrat Rabassa contributed equally to this work.

332 **Funding**

333 This research was supported by the NEOBEFOOD project from the Industrial Technological
334 Development Centre (CDTI) and Company Ordesa S.L. (Spain) in collaboration with the Bosch i
335 Gimpera Foundation (FBG306133) and the award of 2014SGR1566 from the Generalitat de
336 Catalunya's Agency AGAUR. Olha Khymenets and Sara Tulipani thank the postdoctoral “Juan de la

337 Cierva” program, and Mireia Urpi- Sarda thanks the “Ramon y Cajal” program and Fondo Social
338 Europeo, all from the Spanish Ministry of Science and Innovation (MICINN).

339 **Notes**

340 The authors declare no competing financial interest.

341 **ACKNOWLEDGMENTS**

342 The authors are grateful to all of the volunteers who participated in this study.

343 **ABBREVIATIONS USED**

344 BM, breast milk; DCh, dark chocolate; DHPV, 5-(3',4' - dihydroxyphenyl)- γ -valerolactone; FFQ,
345 food frequency questionnaire; Gluc, glucuronide; 24 h DR, 24 h dietary recall; EpiCat, epicatechin;
346 IS, internal standard; Met, methyl; MHPV, 5-(3' -methoxy,4' --hydroxyphenyl)- γ -valerolactone;
347 Sulf, sulfate

348 **REFERENCES**

- 349 (1) Ballard, O.; Morrow, A. L. Human milk composition: Nutrients and bioactive factors. *Pediatr.*
350 *Clin. North Am.* 2013, 60 (1), 49–74.
- 351 (2) Allen, L. H. Multiple micronutrients in pregnancy and lactation: An overview. *Am. J. Clin. Nutr.*
352 2005, 81 (5), 1206S–1212S.
- 353 (3) Visioli, F.; De La Lastra, C. A.; Andres-Lacueva, C.; Aviram, M.; Calhau, C.; Cassano, A.;
354 D'Archivio, M.; Faria, A.; Fave, G.; Fogliano, V.; Llorach, R.; Vitaglione, P.; Zoratti, M.; Edeas, M.
355 Polyphenols and human health: A prospectus. *Crit. Rev. Food Sci. Nutr.* 2011, 51 (6), 524–546.
- 356 (4) Landete, J. M. Updated knowledge about polyphenols: Functions, bioavailability, metabolism,
357 and health. *Crit. Rev. Food Sci. Nutr.* 2012, 52 (10), 936–948.
- 358 (5) Franke, A. A.; Custer, L. J. Daidzein and genistein concentrations in human milk after soy
359 consumption. *Clin. Chem.* 1996, 42 (6), 955–964.

- 360 (6) Franke, A. A.; Halm, B. M.; Custer, L. J.; Tatsumura, Y.; Hebshi, S. Isoflavones in breastfed
361 infants after mothers consume soy. *Am. J. Clin. Nutr.* 2006, 84 (2), 406–413.
- 362 (7) Romaszko, E.; Wiczowski, W.; Romaszko, J.; Honke, J.; Piskula, M. K. Exposure of breastfed
363 infants to quercetin after consumption of a single meal rich in quercetin by their mothers. *Mol. Nutr.*
364 *Food Res.* 2014, 58 (2), 221–228.
- 365 (8) Franke, A. A.; Custer, L. J.; Tanaka, Y. Isoflavones in human breast milk and other biological
366 fluids. *Am. J. Clin. Nutr.* 1998, 68 (6), 1466S–1473S.
- 367 (9) Song, B. J.; Jouni, Z. E.; Ferruzzi, M. G. Assessment of phytochemical content in human milk
368 during different stages of lactation. *Nutrition* 2013, 29 (1), 195–202.
- 369 (10) Perez-Jimenez, J.; Neveu, V.; Vos, F.; Scalbert, A. Identification of the 100 richest dietary
370 sources of polyphenols: An application of the Phenol-Explorer database. *Eur. J. Clin. Nutr.* 2010, 64,
371 S112–S120.
- 372 (11) Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J. P.; Tognolini, M.; Borges, G.; Crozier, A.
373 Dietary (poly)phenolics in human health: Structures, bioavailability, and evidence of protective
374 effects against chronic diseases. *Antioxid. Redox Signaling* 2013, 18 (14), 1818–1892.
- 375 (12) Urpi-Sarda, M.; Monagas, M.; Khan, N.; Llorach, R.; Lamuela-Raventos, R. M.; Jauregui, O.;
376 Estruch, R.; Izquierdo-Pulido, M.; Andres-Lacueva, C. Targeted metabolic profiling of phenolics in
377 urine and plasma after regular consumption of cocoa by liquid chromatography-tandem mass
378 spectrometry. *J. Chromatogr. A* 2009, 1216 (43), 7258–7267.
- 379 (13) Urpi-Sarda, M.; Ramiro-Puig, E.; Khan, N.; Ramos-Romero, S.; Llorach, R.; Castell, M.;
380 Gonzalez-Manzano, S.; Santos-Buelga, C.; Andres-Lacueva, C. Distribution of epicatechin
381 metabolites in lymphoid tissues and testes of young rats with a cocoa-enriched diet. *Br. J. Nutr.* 2010,
382 103 (10), 1393–1397.

- 383 (14) Zamora-Ros, R.; Rabassa, M.; Cherubini, A.; Urpi-Sarda, M.; Bandinelli, S.; Ferrucci, L.;
384 Andres-Lacueva, C. High concentrations of a urinary biomarker of polyphenol intake are associated
385 with decreased mortality in older adults. *J. Nutr.* 2013, 143 (9), 1445–1450.
- 386 (15) United States Department of Agriculture (USDA). USDA Database for the Proanthocyanidin
387 Content of Selected Foods; USDA: Beltsville, MD, 2004.
- 388 (16) United States Department of Agriculture (USDA). USDA Database for the Flavonoid Content
389 of Selected Foods; USDA: Beltsville, MD, 2011.
- 390 (17) United States Department of Agriculture (USDA). USDA Database for the Isoflavone Content
391 of Selected Foods; USDA: Beltsville, MD, 2008
- 392 (18) Neveu, V.; Perez-Jimenez, J.; Vos, F.; Crespy, V.; du Chaffaut, L.; Mennen, L.; Knox, C.; Eisner,
393 R.; Cruz, J.; Wishart, D.; Scalbert, A. Phenol-Explorer: An online comprehensive database on
394 polyphenol contents in foods. *Database* 2010, 2010, bap024.
- 395 (19) Fernandez-Ballart, J. D.; Pinol, J. L.; Zazpe, I.; Corella, D.; Carrasco, P.; Toledo, E.; Perez-
396 Bauer, M.; Martinez-Gonzalez, M. A.; Salas-Salvado, J.; Martin-Moreno, J. M. Relative validity of
397 a semiquantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. *Br.*
398 *J. Nutr.* 2010, 103 (12), 1808–1816.
- 399 (20) Boto-Ordóñez, M.; Urpi-Sarda, M.; Queipo-Ortuno, M. I.; Corella, D.; Tinahones, F. J.; Estruch,
400 R.; Andres-Lacueva, C. Microbial metabolomic fingerprinting in urine after regular dealcoholized
401 red wine consumption in humans. *J. Agric. Food Chem.* 2013, 61 (38), 9166–9175.
- 402 (21) Urpi-Sarda, M.; Garrido, I.; Monagas, M.; Gomez-Cordoves, C.; Medina-Rejon, A.; Andres-
403 Lacueva, C.; Bartolome, B. Profile of plasma and urine metabolites after the intake of almond [*Prunus*
404 *dulcis* (Mill.) D.A. Webb] polyphenols in humans. *J. Agric. Food Chem.* 2009, 57 (21), 10134–
405 10142.

- 406 (22) González-Manzano, S.; González-Paramás, A.; Santos-Buelga, C.; Dueñas, M. Preparation and
407 characterization of catechin sulfates, glucuronides, and methylethers with metabolic interest. *J. Agric.*
408 *Food Chem.* 2009, 57 (4), 1231–1238.
- 409 (23) Langer, S.; Marshall, L. J.; Day, A. J.; Morgan, M. R. Flavanols and methylxanthines in
410 commercially available dark chocolate: A study of the correlation with nonfat cocoa solids. *J. Agric.*
411 *Food Chem.* 2011, 59 (15), 8435–8441.
- 412 (24) Berlin, C. M.; Briggs, G. G. Drugs and chemicals in human milk. *Semin. Fetal Neonatal Med.*
413 2005, 10 (2), 149–159.
- 414 (25) Ottaviani, J. I.; Momma, T. Y.; Kuhnle, G. K.; Keen, C. L.; Schroeter, H. Structurally related (
415 –)-epicatechin metabolites in humans: Assessment using de novo chemically synthesized authentic
416 standards. *Free Radical Biol. Med.* 2012, 52 (8), 1403–1412.
- 417 (26) Actis-Goretta, L.; Leveques, A.; Giuffrida, F.; Romanov- Michailidis, F.; Viton, F.; Barron, D.;
418 Duenas-Paton, M.; Gonzalez- Manzano, S.; Santos-Buelga, C.; Williamson, G.; Dionisi, F.
419 Elucidation of (–)-epicatechin metabolites after ingestion of chocolate by healthy humans. *Free*
420 *Radical Biol. Med.* 2012, 53 (4), 787–795.
- 421 (27) van Duynhoven, J.; van der Hooft, J. J.; van Dorsten, F. A.; Peters, S.; Foltz, M.; Gomez-Roldan,
422 V.; Vervoort, J.; De Vos, R. C.; Jacobs, D. M. Rapid and sustained systemic circulation of conjugated
423 gut microbial catabolites after single-dose black tea extract consumption. *J. Proteome Res.* 2014, 13
424 (5), 2668–2678.
- 425 (28) Monagas, M.; Urpi-Sarda, M.; Sanchez-Patan, F.; Llorach, R.; Garrido, I.; Gomez-Cordoves, C.;
426 Andres-Lacueva, C.; Bartolome, B. Insights into the metabolism and microbial biotransformation of
427 dietary flavan-3-ols and the bioactivity of their metabolites. *Food Funct.* 2010, 1 (3), 233–253.
- 428 (29) Begg, E. J.; Duffull, S. B.; Hackett, L. P.; Ilett, K. F. Studying drugs in human milk: Time to
429 unify the approach. *J. Hum. Lact.* 2002, 18 (4), 323–332.

- 430 (30) Bolca, S.; Van de Wiele, T.; Possemiers, S. Gut metabotypes govern health effects of dietary
431 polyphenols. *Curr. Opin. Biotechnol.* 2013, 24 (2), 220–225.
- 432 (31) Cardona, F.; Andres-Lacueva, C.; Tulipani, S.; Tinahones, F. J.; Queipo-Ortuno, M. I. Benefits
433 of polyphenols on gut microbiota and implications in human health. *J. Nutr. Biochem.* 2013, 24 (8),
434 1415– 1422.
- 435 (32) Vogiatzoglou, A.; Mulligan, A. A.; Luben, R. N.; Lentjes, M. A.; Heiss, C.; Kelm, M.; Merx,
436 M. W.; Spencer, J. P.; Schroeter, H.; Kuhnle, G. G. Assessment of the dietary intake of total flavan-
437 3-ols, monomeric flavan-3-ols, proanthocyanidins and theaflavins in the European Union. *Br. J. Nutr.*
438 2014, 111 (8), 1463–1473.
- 439 (33) Knaze, V.; Zamora-Ros, R.; Lujan-Barroso, L.; Romieu, I.; Scalbert, A.; Slimani, N.; Riboli, E.;
440 van Rossum, C. T.; Bueno-de- Mesquita, H. B.; Trichopoulou, A.; Dilis, V.; Tsiotas, K.; Skeie, G.;
441 Engeset, D.; Quiros, J. R.; Molina, E.; Huerta, J. M.; Crowe, F.; Wirfal, E.; Ericson, U.; Peeters, P.
442 H.; Kaaks, R.; Teucher, B.; Johansson, G.; Johansson, I.; Tumino, R.; Boeing, H.; Drogan, D.;
443 Amiano, P.; Mattiello, A.; Khaw, K. T.; Luben, R.; Krogh, V.; Ardanaz, E.; Sacerdote, C.; Salvini,
444 S.; Overvad, K.; Tjonneland, A.; Olsen, A.; Boutron-Ruault, M. C.; Fagherazzi, G.; Perquier, F.;
445 Gonzalez, C. A. Intake estimation of total and individual flavan-3-ols, proanthocyanidins and
446 theaflavins, their food sources and determinants in the European Prospective Investigation into
447 Cancer and Nutrition (EPIC) study. *Br. J. Nutr.* 2012, 108 (6), 1095–1108.
- 448 (34) Neville, M. C.; Morton, J.; Umemura, S. Lactogenesis. The transition from pregnancy to
449 lactation. *Pediatr. Clin. North Am.* 2001, 48 (1), 35–52.




Figure 1. Scheme of population study with 11 free-living lactating women. (*) Some data/samples were collected twice from the same volunteer at different time points.

452




Figure 2. Postprandial (12 h) host epicatechin metabolites in BM: (A) metabolite concentrations (lines) versus their cumulative excretion (bars) in BM of volunteer 2 and (B) kinetics of detected metabolites in BM of both volunteers.

453

454

455

TABLES

Table 1. Bivariate Correlation between Dietary Intake of Flavan-3-ols and Levels of DHPV-Sulf-2, a Microbial Metabolite of Epicatechin, Detected in BM Samples of Free-Living Breastfeeding Mothers^a

		bivariate Spearman correlations [<i>r</i> (<i>p</i> value)]	
		24 h DR versus DHPV-Sulf2 (<i>n</i> = 24) ^b	24 h DR (Tr + M) versus DHPV-Sulf2 (<i>n</i> = 21) ^b
cocoa food	flavan-3-ols ^c	0.201 (0.347)	0.332 (0.142)
	EpiCat	0.273 (0.197)	0.434 (0.049)
total diet	flavan-3-ols ^c	0.064 (0.767)	0.126 (0.586)
	EpiCat	0.079 (0.715)	0.140 (0.544)

^aEpiCat, epicatechin; DHPV, 5-(3',4'-dihydroxyphenyl)- γ -valerolactone; 24 h DR, 24 h dietary recall; M, mature (BM); Sulf, sulfate; and Tr, transition (BM). ^bSamples (BM corresponding to their dietary data) are considered as independent measurements. ^cTotal dietary and cocoa flavan-3-ol monomers were expressed as aglycone equivalents (mg/day) and were calculated as the sum of catechin, catechin-3-gallate, epicatechin, epicatechin-3-gallate, epigallocatechin, epigallocatechin-3-gallate, and galocatechin.

Table 1.